The consensus on tertiary prevention of primary liver cancer (2022 version).
10.3760/cma.j.cn501113-20220616-00330
- Collective Name:Chinese Society of Hepatology, Chinese Medical Association
- Publication Type:Journal Article
- MeSH:
China/epidemiology*;
Consensus;
Humans;
Liver Neoplasms/prevention & control*;
Survival Rate;
Tertiary Prevention
- From:
Chinese Journal of Hepatology
2022;30(8):832-845
- CountryChina
- Language:Chinese
-
Abstract:
In order to effectively prevent recurrence, improve the prognosis and increase the survival rate of primary liver cancer (PLC) patients with radical cure, the Chinese Society of Hepatology, Chinese Medical Association organized the relevant experts to develop the consensus on tertiary prevention of PLC (2022 version), which based on domestic and international research progress on the risk factors, pathological and clinical features, prevention of recurrence of PLC, combined with the present actual situation in China. The purpose is to provide a current basis for the prevention, surveillance, early detection and diagnosis, the effective measures of PLC recurrence.
